Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
Dr. Rousseau to lead clinical development as Pheast advances PHST001, a novel anti-CD24 macrophage checkpoint inhibitor, into clinical trials Pheast Therapeutics, a private biotechnology company...